The AI chatbot reckons these stocks in my my SIPP and Stocks and Shares ISA portfolios could be negatively impacted by artificial intelligence.

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...

We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

European stocks were mostly higher after a court stuck down Trump's sweeping tariff agenda. The Court of International Trade on Wednesday ruled that Trump wrongfully invoked an emergency law to impose ...

Denmark's Novo Nordisk faces mounting pressure — from cheap copycats to US tariff threats — putting its weight-loss empire at ...

Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...